Binding of anti - Platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4

Blood

Volumn 124, Issue 15, 2014, Pages 2442-2449

  Kreimann, Martin ^a   Brandt, Sven ^a   Krauel, Krystin ^b   Block, Stephan ^a   Helm, Christiane A ^c   Weitschies, Werner ^d   Greinacher, Andreas ^b   Delcea, Mihaela ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^c Institut fur Physik   (Germany)

^d Institut für Pharmazie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; FONDAPARINUX; HEPARIN; HEPARIN ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; THROMBOCYTE FACTOR 4; THROMBOCYTE FACTOR 4 ANTIBODY; UNCLASSIFIED DRUG; POLYSACCHARIDE; PROTEIN BINDING;

ARTICLE; ATOMIC FORCE MICROSCOPY; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; DRUG PROTEIN BINDING; HUMAN; ISOTHERMAL TITRATION CALORIMETRY; PROTEIN INTERACTION; THERMODYNAMICS; CALORIMETRY; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; PROTEIN SECONDARY STRUCTURE;

ANTIBODIES; CALORIMETRY; CIRCULAR DICHROISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MICROSCOPY, ATOMIC FORCE; PLATELET FACTOR 4; POLYSACCHARIDES; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; THERMODYNAMICS;

EID: 84907658455     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-559518     Document Type: Article

References (38)

1. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451(7181):914-918.
2. Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Sims GE. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration. Thromb Res. 1976;9(6):575-583.
3. Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J. 1984;218(3):725-732.
4. Walenga JM, Jeske WP, Samama MM, Frapaise FX, Bick RL, Fareed J. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs. 2002;11(3):397-407.
5. Xu Y, Masuko S, Takieddin M, et al. Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins. Science. 2011;334(6055):498-501.
6. Petitou M, Hérault JP, Bernat A, et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature. 1999;398(6726):417-422.
7. Mousa SA, Petersen LJ. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost. 2009;102(2):258-267.
8. Greinacher A. Heparin-induced thrombocytopenia. J Thromb Haemost. 2009;7(Suppl 1):9-12.
9. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330-1335.
10. Rauova L, Poncz M, McKenzie SE, et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood. 2005;105(1):131-138.
11. Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood. 2006;107(6):2346-2353.
12. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101(5):502-507.
13. Sachais BS, Litvinov RI, Yarovoi SV, et al. Dynamic antibody-binding properties in the pathogenesis of HIT. Blood. 2012;120(5):1137-1142.
14. Greinacher A, Gopinadhan M, Günther JUG, et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol. 2006;26(10):2386-2393.
15. Suvarna S, Espinasse B, Qi R, et al. Determinants of PF4/heparin immunogenicity. Blood. 2007;110(13):4253-4260.
16. Chudasama SL, Espinasse B, Hwang F, et al. Heparin modifies the immunogenicity of positively charged proteins. Blood. 2010;116(26):6046-6053.
17. Brandt S, Krauel K, Gottschalk KE, et al. Characterization of the conformational changes in platelet factor 4 induced by polyanions: towards in-vitro prediction of antigenicity. Thrombosis Haemostasis. 2014;112(1):53-64.
18. Shastri MD, Peterson GM, Stewart N, Sohal SS, Patel RP. Non-anticoagulant derivatives of heparin for the management of asthma: distant dream or close reality? Expert Opin Investig Drugs. 2014;23(3):357-373.
19. Juhl D, Eichler P, Lubenow N, Strobel U, Wessel A, Greinacher A. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol. 2006;76(5):420-426.
20. Böhm G, Muhr R, Jaenicke R. Quantitative analysis of protein far UV circular dichroism spectra by neural networks. Protein Eng. 1992;5(3):191-195.
21. Cornelsen M, Helm CA, Block S. Destabilization of polyelectrolyte multilayers formed at different temperatures and ion concentrations. Macromolecules. 2010;43(9):4300-4309.
22. Stranak V, Block S, Drache S, et al. Size-controlled formation of Cu nanoclusters in pulsed magnetron sputtering system. Surf Coat Tech. 2011;205(8-9):2755-2762.
23. Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis. 1997;8(2):114-117.
24. Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost. 1995;74(3):886-892.
25. Ahmad S, Jeske WP, Walenga JM, et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost. 1999;5(4):259-266.
26. Laugel N, Betscha C, Winterhalter M, Voegel JC, Schaaf P, Ball V. Relationship between the growth regime of polyelectrolyte multilayers and the polyanion/polycation complexation enthalpy. J Phys Chem B. 2006;110(39):19443-19449.
27. Sperber BL, Cohen Stuart MA, Schols HA, Voragen AG, Norde W. Overall charge and local charge density of pectin determines the enthalpic and entropic contributions to complexation with b-lactoglobulin. Biomacromolecules. 2010;11(12):3578-3583.
28. Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med. 2001;138(1):22-31.
29. Amiral J, Bridey F, Wolf M, et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost. 1995;73(1):21-28.
30. Greinacher A. Antigen generation in heparin-associated thrombocytopenia: the nonimmunologic type and the immunologic type are closely linked in their pathogenesis. Semin Thromb Hemost. 1995;21(1):106-116.
31. Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost. 1992;67(5):545-549.
32. Greinacher A, Pötzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;71(2):247-251.
33. Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl. 2002;41(3):391-412.
34. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005;106(12):3791-3796.
35. Krauel K, Pötschke C, Weber C, et al. Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood. 2011;117(4):1370-1378.
36. Jaax ME, Krauel K, Marschall T, et al. Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4. Blood. 2013;122(2):272-281.
37. Kasahara K, Kaneda M, Miki T, et al. Clot retraction is mediated by factor XIII-dependent fibrin-αIIbß3-myosin axis in platelet sphingomyelin-rich membrane rafts. Blood. 2013;122(19):3340-3348.
38. Kremer Hovinga JA, Lammle B. Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2012;2012(1):610-616.